Marc Schneebaum joined Avalyn as CFO in September 2021. Mr. Schneebaum has over 25 years of experience in the biotechnology and healthcare sector.

Prior to Avalyn, Mr. Schneebaum served as SVP and chief financial officer of Madrigal Pharmaceuticals, Inc., a company developing drugs for liver and cardiovascular diseases, including NASH. He also was SVP and chief financial officer of Synta Pharmaceuticals, Inc., a company developing oncology drugs and president, chief executive officer and a director of Predictive BioSciences, Inc., a commercial stage oncology diagnostics company. Mr. Schneebaum has also served as president, chief executive officer, and a director of Sensors for Medicine and Science, Inc., an emerging medical technology company; SVP of finance, business development and administration, and chief financial officer of Genetic Therapy, Inc., a biotechnology company (acquired by Sandoz/Novartis).

Mr. Schneebaum was a VP at Alex. Brown & Sons Incorporated, a leading investment banking firm, where he participated in a variety of finance and strategic assignments, and he began his career in the accounting and auditing group at KPMG LLP, advancing to senior manager in the management consulting group. Mr. Schneebaum served as a director of GenVec, Inc., a publicly held biopharmaceutical company acquired by Intrexon Corporation, from 2007 to 2017, and as a director of several privately held life science companies. Mr. Schneebaum earned his degree in business administration from the University of Maryland.